CLINICAL ROLE -
Pandemic Pricing: The Risks and Rewards of Fast-Tracking Value-Based Drug Evaluations
As we consider the implications of the COVID-19 pandemic and the release of remdesivir, ICER’s expedited evaluation raises some questions related to value-based pricing evaluations.
Read More